PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsDiagnosis and subclassification of acute lymphoblastic leukemiaThe molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.Prognostification of ALL by CytogeneticsUse of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemiaBiochemical and functional studies of lymphoid-specific tyrosine phosphatase (Lyp) variants S201F and R266WIdentification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.The molecular regulation of Janus kinase (JAK) activationA RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2).TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy.Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments.Src family kinases and their role in hematological malignancies.Genomic characterization of acute leukemias.DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.Significance of Inactivated Genes in Leukemia: Pathogenesis and PrognosisLoss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.TC-PTP regulates the IL-7 transcriptional response during murine early T cell development.Mutant JAK3 signaling is increased by loss of wild type JAK3 or by acquiring secondary JAK3 mutations in T-ALL.A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.The impact of phosphatases on proliferative and survival signaling in cancer.The Role of TCPTP in Cancer
P2860
Q26782539-15FD8692-C1A6-47ED-9721-9362DBB05E24Q26824387-AAF2E78A-40EE-48CB-95FC-B207E88D81DAQ27852046-075306D6-9DFC-4776-998B-81FBA85A4C29Q28087446-D7558FB2-F7B5-4B2D-A0EB-8B34E5ECC4F2Q28390558-4D5A0EFA-80D2-434D-9403-FD2140DFC87FQ28482717-9EB1093B-8156-42DE-938E-05192CF5DE74Q33798544-4DF4141C-7979-450F-9AD9-748B0A07429BQ33956113-40F446B0-AAD4-41BF-B118-EF12DB15D1A0Q35682010-AA4B6A63-FE36-4C90-822C-F31C1CC838C6Q36560020-14B140E7-F393-486A-96DA-831F80BD9802Q36883348-75743331-9A47-4D8F-82DC-1F2C49EEFFCEQ38005040-45F450D6-D7B7-49AD-AC7E-A5EB37B3F49BQ38217719-26BF6CB3-A815-4D80-B02F-53B84728D4D2Q38223490-EDD32BF9-FD95-4814-9069-F9F609796845Q39094566-30E33391-09ED-4905-AF38-2EA2DE159523Q39350173-E1A07E96-648B-474C-B308-D423E5CD1B92Q41550474-1787710B-9391-4AF6-B1D3-864861354186Q41660964-63FB6672-CFFE-4036-91F9-190D785F2FE0Q42378868-D17D82FF-05AF-456E-81AA-E97AB9FD0995Q47395580-424D1540-16ED-4293-9B90-D55B1D395A97Q47557998-1AE48357-16B7-43FF-8AB7-B76B768E44D4Q50882019-AF2FAFDD-B7D6-4312-8C75-57C8692ED599Q51323736-A6148A03-AEC9-44B9-8455-232747218E49Q52718168-1F7509A2-DBBD-4454-ADB9-2E71A600648EQ54112403-0C46F674-D6ED-4665-AF50-E63DDC37C96DQ58377593-ADC6C003-CE89-4CB3-B3B5-3C5F5D7F3AE5
P2860
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
@en
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
@nl
type
label
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
@en
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
@nl
prefLabel
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
@en
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
@nl
P2093
P50
P1433
P1476
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
@en
P2093
Elizabeth Macintyre
François Sigaux
Jean Soulier
Laurent Knoops
Maria Kleppe
Nicole Mentens
Tekla Hornakova
Vahid Asnafi
P304
P356
10.1182/BLOOD-2010-10-314286
P407
P50
P577
2011-05-06T00:00:00Z